SPR Therapeutics and its parent company, NDI Medical, received a $2.77 million Peer Reviewed Orthopaedic Research Program Clinical Trial Award to advance SPR’s Peripheral Nerve Stimulation therapy to relieve post-amputation pain, according to a press release.
Awarded by the US Department of Defense, the grant award is a result of the successful completion of SPR’s post-amputation pain feasibility study, in which the majority of study participants reported substantial pain relief, as well as a significant impact on quality of life. The SPR Peripheral Nerve Stimulation (PNS) System uses a proprietary method of nerve stimulation to treat pain without requiring the electrodes to be surgically implanted or in direct contact with the peripheral nerves that carry the pain signal. The next phase of clinical research will be supported by the grant award.
“The funding of our project for improving the functional outcomes of combat-injured warfighters using SPR’s PNS Therapy is a significant milestone for SPR and NDI,” Geoff Thrope, founder, president and chief executive officer of NDI, said in the release. “We are grateful to the US Department of Defense as this grant further validates the strength of our team and our work in developing innovative neurodevice technologies to address significant unmet health conditions and improve patients’ lives.”
